Prof. Bangde Xiang 向邦德
Chief Physician, Professor
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of liver, gallbladder, and pancreatic tumors, with a focus on the diagnosis and comprehensive treatment of liver cancer.
Dr. Xiang holds an MD from Hunan Medical University (1999) and a PhD from Sun Yat-sen University (2005). Dr. Xiang completed advanced training at Fudan University Zhongshan Hospital and University Medical Center Hamburg-Eppendorf, Germany. Research focuses on surgical treatment and basic research of hepatobiliary and pancreatic malignancies, particularly primary liver cancer. Dr. Xiang leads projects funded by the National Natural Science Foundation and Guangxi Natural Science Foundation.
Professional roles
- Vice Chair, Youth Committee of Liver Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Liver Cancer Professional Committee, Guangxi Anti-Cancer Association
- Standing Committee Member, Tumor Recurrence and Metastasis Professional Committee, Guangxi Anti-Cancer Association
- Standing Committee Member and Secretary, General Surgery Branch, Guangxi Medical Doctor Association
Name order: in Chinese the family name comes first (Xiang Bangde). Papers usually list the name as Bangde Xiang or Xiang B.
Selected publications
111 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): All deaths follow recurrence, but not all recurrences are fatal: a retrospective cohort study of recurrence timing and survival after curative resection of hepatocellular carcinoma. PubMed 43016633
- Cancers (Basel), 2026 (senior author): SPINT2 Is Associated with Dual-Phenotype Hepatocellular Carcinoma and Aggressive Tumor Features. PubMed 42882797
- Front Immunol, 2026 (senior author): Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: a multicenter study integrating major pathological response and treatment duration. PubMed 42835116
- Eur J Surg Oncol, 2026 (senior author): One-stage hepatectomy may be a safe and feasible alternative to ALPPS for hepatocellular carcinoma with liver fibrosis or cirrhosis and FLR/SLV ratio of 30% - 40% - A multicenter study. PubMed 42296572
- Eur J Surg Oncol, 2026 (senior author): Wide resection margin fails to demonstrate improved survival outcomes in early-stage hepatocellular carcinoma following anatomical resection: A propensity score-matched analysis from two tertiary centers. PubMed 42150294
- Oncol Lett, 2026 (senior author): Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma. PubMed 41987864
- Cardiovasc Diabetol, 2026 (senior author): Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies. PubMed 42046117
- BMC Cancer, 2026 (senior author): CK7-positive hepatocellular carcinoma represents a distinct subtype: a retrospective cohort study. PubMed 41981525
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion